Conway Capital Management Inc. Makes New $119,000 Investment in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)

Conway Capital Management Inc. purchased a new stake in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 10,000 shares of the company’s stock, valued at approximately $119,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Barclays PLC raised its holdings in shares of Olema Pharmaceuticals by 105.0% in the 3rd quarter. Barclays PLC now owns 94,915 shares of the company’s stock valued at $1,133,000 after purchasing an additional 48,614 shares during the period. XTX Topco Ltd raised its stake in Olema Pharmaceuticals by 103.4% in the third quarter. XTX Topco Ltd now owns 25,332 shares of the company’s stock valued at $302,000 after buying an additional 12,878 shares during the period. EP Wealth Advisors LLC raised its stake in Olema Pharmaceuticals by 5.2% in the third quarter. EP Wealth Advisors LLC now owns 48,655 shares of the company’s stock valued at $581,000 after buying an additional 2,407 shares during the period. Wellington Management Group LLP lifted its position in shares of Olema Pharmaceuticals by 10.8% in the third quarter. Wellington Management Group LLP now owns 1,002,685 shares of the company’s stock valued at $11,972,000 after buying an additional 97,428 shares during the last quarter. Finally, State Street Corp boosted its stake in shares of Olema Pharmaceuticals by 1.1% during the 3rd quarter. State Street Corp now owns 1,969,963 shares of the company’s stock worth $23,521,000 after acquiring an additional 21,986 shares during the period. Institutional investors own 91.78% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and issued a $30.00 price target on shares of Olema Pharmaceuticals in a research note on Wednesday, November 13th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $27.00.

Olema Pharmaceuticals Stock Down 9.7 %

Shares of OLMA stock opened at $9.44 on Tuesday. Olema Pharmaceuticals, Inc. has a 12-month low of $7.68 and a 12-month high of $16.77. The company has a market capitalization of $540.89 million, a PE ratio of -4.31 and a beta of 1.92. The firm has a 50 day moving average price of $11.07 and a two-hundred day moving average price of $11.93.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.